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Autologous stem cell transplant is feasible in very elderly 
patients with lymphoma and limited comorbidity
Rebecca L. Elstrom, Peter Martin, Sandra Hurtado Rua, Tsiporah B. Shore, Richard R. Furman, Jia 
Ruan, Roger N. Pearse, Morton Coleman, Tomer Mark, John P. Leonard, and Usama Gergis
In patients with recurrent Hodgkin or non-Hodgkin’s lymphoma, autol-
ogous stem cell transplantation (ASCT) can offer potential for cure or
long-term remission. Because of potential toxicity, elderly patients are
usually not considered candidates, but data regarding tolerability and
efﬁcacy in this group are lacking. The transplant database at Weill Cor-
nell Medical College was reviewed to identify patients with lymphoma
undergoing ASCT at age 69 or greater. Clinical data and comorbidities
were correlated with outcome. Twenty-one patients were identiﬁed.
Sixteen of 19 evaluable patients (76%) achieved complete remission
following ASCT, while 2 patients died before response assessment.
Median progression-free survival following ASCT was 8 months and
median overall survival was 18 months. Age was not predictive of
overall survival, but patients 75 and older had inferior progression-free
survival compared to younger patients. High-risk status by hemato-
poietic stem cell transplant comorbidity index (HCT-CI) was associated
with short overall survival and high transplant-related mortality. ASCT
is feasible and of potential beneﬁt in selected elderly lymphoma
patients. Consideration of comorbidities, rather than age alone, may
allow selection of patients likely to tolerate and beneﬁt from ASCT.
Non Hodgkin’s lymphoma increases in incidence with advanced age. High
dose chemotherapy with autologous stem cell transplantation (ASCT) plays
an important therapeutic role, particularly in patients with chemosensitive
relapses of curable histologies such as diffuse large B cell (DLBCL) and
Hodgkin lymphoma (HL), but many patients have not been considered eligi
ble for this approach due to advanced age. The question of whether age
alone should be an exclusionary factor for ASCT is controversial.
Recent single center retrospective studies reported conﬂicting results on the
impact of age on transplant outcomes. While limited data demonstrating its
feasibility in patients >60 years of age are available, most of the patients
included in these studies are between the ages of 60 and 70. Although some
reports have suggested higher than expected nonrelapse mortality (NRM) in
patients over 60 years of age [1], this ﬁnding is not consistent [2 5].
Comorbidity refers to a medical condition existing simultaneously with but
independently of a primary disorder. The Charlson comorbidity index [6]
(CCI) was developed as a tool to predict mortality in hospitalized patients,
assigning a weight to a variety of disorders such as diabetes mellitus, liver
dysfunction or pulmonary disease, together deﬁning a score which is predic
tive of mortality. The hematopoietic stem cell transplant comorbidity index
(HCTCI) [7] represents a modiﬁcation of the CCI to better represent comor
bidities identiﬁed in the allogeneic stem cell transplant population. Major dif
ferences between these indices include incorporation of objective data for
measurement of pulmonary, renal, and hepatic dysfunction, in addition to
symptoms, and consideration of any prior malignancy as a risk factor, not
just malignancies initially treated within 5 years of transplantation. The pres
ence of signiﬁcant comorbidities, as measured by the CCI or HCTCI, predis
poses to increased toxicity in patients over 60, but this factor has been
inconsistently associated with mortality.
Many patients in the eighth decade of life or beyond have excellent per
formance status and prelymphoma overall health. At our center, age has not
been routinely used as an exclusion criterion for this treatment modality. We
therefore examined outcomes of patients who were 69 and older at the time
of transplantation to determine whether ASCT is feasible in this population,
and whether comorbidities are predictive of NRM and overall survival (OS).
Twenty one patients aged 69 or greater (range 69 86, median 71) were
identiﬁed who had undergone autologous stem cell transplant for lymphoma
and had records available for review; characteristics are shown in Table I.
Five patients were 75 years of age or older, and 2 patients were over the
age of 80 (83 and 86 years old).
All patients underwent cytotoxic conditioning regimens and subsequently
received autologous stem cells. Conditioning regimens for most patients
consisted of BCNU, cyclophosphamide, and etoposide (BCV), BCNU, etopo
side, cytarabine, and melphalan (BEAM), or similar regimens. Two patients
were treated with cyclophosphamide and total body irradiation (TBI), and
one received mitoxantrone, thiotepa, and cyclophosphamide.
Neutrophil engraftment occurred in 19 patients, while 2 patients died
before engraftment could be evaluated. Platelet engraftment occurred in 16
patients, while 3 remained platelet transfusion dependent. Median time to
neutrophil engraftment was 11 days (range 9 26 days), and median time to
platelet engraftment was 21 days (range 13 51 days).
Sixteen patients (76%) achieved a complete remission (CR) following
ASCT, while three patients did not achieve CR. Two patients (10%), ages 73
and 75, died of infection before engraftment and were unable to undergo
response assessment. Two more patients, ages 70 and 73, died within or
shortly after 100 days of treatment related complications (infection and car
diac arrhythmia), for a total of 4 (19%) early treatment related deaths
(TRM). At median follow up of 25 months (range 7 48 months), median pro
gression free survival (PFS) was 8 months (Fig. 1A) and median overall sur
vival (OS) was 18 months (Fig. 1B). Ten patients (48%) survived in remis
sion for at least 1 year following transplant.
Eight patients were alive at last follow up, of whom 7 remained in remis
sion, while 13 patients had died. Of the eight deaths that occurred within the
ﬁrst year, four patients died of TRM and four died due to progressive lym
phoma. Five deaths occurred more than 1 year after transplant: two patients
died of progressive lymphoma, one died of unknown causes, one died of
secondary AML at 3 years, and one died of intracranial hemorrhage 4 years
following transplantation.
Progression free survival was superior in younger patients when com
pared to those 75 and older (P 5 0.004). However, although there was a
trend to better overall survival in younger patients, this trend did not reach
statistical signiﬁcance (P 5 0.084). Conditioning regimen was not predictive
of either PFS or OS. There was no association between CD341 cell dose,
time to neutrophil engraftment, or time to platelet engraftment and either
PFS or OS.
HCTCI and CCI were calculated for all patients (Table II). Using the HCT
CI, three patients were of high risk, eight patients were intermediate risk,
and ten patients were low risk. Using the CCI, one patient was of high risk,
TABLE I. Demographics
Age: median (range) 71 (69 86)
69 70 9
71 74 7
75 86 5
Gender
Male 13
Female 8
Histology
DLBCL 13
Transformed 3
Burkitt 2
PTCL 1
FL 1
HL 1
Disease status
Second remission 16
Third or greater remission 2
Primary refractory 2
First complete remission 1
CCI
Low risk 13
Intermediate risk 7
High risk 1
HCT-CI
Low risk 10
Intermediate risk 8
High risk 3
seven had intermediate risk, and thirteen were low risk. Considering the four
patients who died within 100 days of TRM, three were high risk by HCTCI,
and one was low risk, whereas using the CCI, one patient was considered
high risk, two intermediate risks, and one low risk. Although there was no
difference in OS between low and intermediate risk patients by either index,
patients determined to be high risk by HCT CI experienced extremely poor
survival, as shown in Fig. 2 (median 0.3 months vs. 19 months for nonhigh
risk patients, P 5 0.000005). Only one patient was identiﬁed to be high risk
by CCI, limiting the predictive utility of this index.
In summary, we sought to assess the feasibility of ASCT for lymphoma in
a group of very elderly patients and to evaluate the utility of pretransplant
validated comorbidity assessments to predict outcome. Our data show that
autologous stem cell transplantation is feasible and of potential beneﬁt in
selected very elderly patients with lymphoma.
Others have studied the impact of age on toxicity and mortality in the
setting of stem cell transplantation. Although some have reported
increased toxicity and/or TRM in patients over 60 as compared to
younger patients [1,8 10], others have not observed this difference [2 5].
Two previous reports have evaluated the impact of comorbidities on out
come in older patients undergoing ASCT. Wildes et al. [2] compared 59
patients aged 60 and older to younger patients, showing no difference
overall in DFS or OS, but a signiﬁcant impact of CCI on TRM and OS.
Hosing et al. [3] found that, in patients over age 65 undergoing ASCT,
HCTCI predicted for increased toxicity during transplant, but had no
impact on OS.
Andorsky et al. recently published the ﬁrst data of which we are aware
evaluating ASCT in lymphoma patients 70 years of age and older [11]. In
this small group of 17 patients, 1 year nonrelapse mortality was 35%. CCI
and HCTCI were calculated but were not predictive for survival in this group.
No pretransplant characteristics were identiﬁed that could help identify
patients who would be at prohibitively high risk of this procedure.
HCT CI was predictive of survival in the group of patients presented here,
supporting previous reports in younger patients that comorbidities are likely
a more important factor in determining potential beneﬁt of transplant than
age. Although it is not clear why our results differ from those of Andorsky
et al., it is possible that it relates to either the very small sample size or lack
of inclusion of higher risk patients in the Andorsky report. In our small
cohort, the HCTCI was more sensitive than the CCI in capturing high risk
patients. In fact, 3 out of 4 (75%) patients who died within 100 days of trans
plant were identiﬁed as high risk by the HCTCI. This could be the basis for
testing the validity of the HCTCI in ASCT in elderly patients, and possibly
across all age groups.
Within this elderly population, when patients 75 and older were compared to
those <74 years of age, lymphoma speciﬁc outcomes appeared inferior. This
ﬁnding suggests that, although ASCT appears to be tolerable in the setting of
limited comorbidity, it may be less effective therapy for this older group of
patients. Given the limited numbers and lack of statistical power, ﬁrm conclu
sions regarding the impact of age alone will require a larger sample size.
We recognize several limitations to our study, including the retrospec
tive nature of the data collection with potential associated selection bias,
the fact that it is a single institution experience, and the small sample
size, limiting ﬁrm conclusions regarding association of clinical factors
with outcome. Notwithstanding these shortcomings, our ﬁndings extend
ASCT as a feasible option in a selected group of very elderly patients.
The paucity of published data addressing aggressive treatment options
in this age group calls for more effort to discern patients who can bene
ﬁt from this approach.
In conclusion, age alone need not be an exclusionary factor for ASCT in
elderly patients with lymphoma. Selected patients with limited comorbidities
can beneﬁt from this treatment modality in spite of advanced age.
Methods
We identiﬁed all patients age 69 or greater with a diagnosis of Hodgkin
lymphoma (HL) or non Hodgkin’s lymphoma (NHL) who underwent ASCT
between June 2003 and December 2009. Patients were identiﬁed by review
of the stem cell transplant database at Weill Cornell Medical College. Age,
Figure 1. (A) Progression free survival for all patients. (B) Overall survival for all
patients.
Figure 2. Kaplan Meier estimate of overall survival by HCTCI (risk factor 1:
low and intermediate versus 2: high risk). Patients of high risk by HCTCI have
inferior overall survival when compared to those of low or intermediate risk (P 5
0.000005).
date of transplant, conditioning regimen, engraftment data (neutrophils and
platelets), response, and survival data were derived from review of medical
records. Determination of candidacy for ASCT and conditioning regimen
were at the discretion of the treating physician.
Baseline Charlson comorbidity risk index (CCI) and hematopoietic stem
cell transplant comorbidity index (HCTCI) were calculated for all patients.
Comorbidity data were collected from review of medical records, and comor
bidities were scored as previously published [6,7]. For both indices, a score
of 0 was deﬁned as low risk, a score of 1 2 was deﬁned as intermediate
risk, and a score of 3 or higher was considered high risk. Comorbidity risk
scores were correlated with NRM, OS, and PFS.
Primary endpoints for the analysis were progression free survival (PFS) and
overall survival (OS). OS was deﬁned as the time from transplant until death
or last follow up, and PFS was deﬁned as the time from transplant until dis
ease progression, death or last follow up. Treatment related mortality (TRM)
was deﬁned as death within 100 days of transplant not attributed to progres
sion of lymphoma. Analyses of OS and PFS were performed using the
Kaplan Meier method [12]. Conﬁdence intervals were computed using a 95%
conﬁdence level. Conﬁdence intervals for the median survival times were com
puted using Brookmeyer and Crowley method [13]. Analysis was carried out
using R A language and environment for statistical computing [14].
This study was reviewed and approved by the Investigational Review
Board of Weill Cornell Medical College.
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